Optimisation of scan duration and image quality in oncological ⁸⁹ Zr immunoPET imaging using the Biograph Vision PET/CT.

Autor: van Sluis J; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. j.van.sluis@umcg.nl., Boellaard R; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.; Department of Radiology and Nuclear Medicine, University Medical Centers Amsterdam, Free University of Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands., Dierckx RAJO; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., van Esch ELM; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Croes DA; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., de Ruijter LK; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Noordzij W; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jul; Vol. 50 (8), pp. 2258-2270. Date of Electronic Publication: 2023 Mar 22.

⁸⁹ Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.

Autor: Verhoeff SR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Aarntzen EHJG; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Miedema IHC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Voortman J; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Menke-van der Houven van Oordt WC; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Boellaard R; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Vriens D; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands., Slingerland M; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Hermsen R; Department of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands; and., Grunsven IVE; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Heskamp S; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; Carla.vanherpen@radboudumc.nl.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Oct; Vol. 63 (10), pp. 1523-1530. Date of Electronic Publication: 2022 May 05.

⁸⁹ Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.

Autor: Kok IC; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Hooiveld JS; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Giesen D; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van der Veen EL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Lub-de Hooge MN; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Brouwers AH; Department of Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Hiltermann TJN; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van der Wekken AJ; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Hijmering-Kappelle LBM; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Elias SG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Groen HJM; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Uyterlinde W; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Hiel B; Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JB; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Jalving M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: e.g.e.de.vries@umcg.nl.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Jan; Vol. 33 (1), pp. 80-88. Date of Electronic Publication: 2021 Nov 01.

Molecular imaging biomarkers for immune checkpoint inhibitor therapy.

Autor: van de Donk PP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Kist de Ruijter L; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Lub-de Hooge MN; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., van der Wekken AJ; Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Fehrmann RS; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., de Vries EG; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Publikováno v: Theranostics [Theranostics] 2020 Jan 01; Vol. 10 (4), pp. 1708-1718. Date of Electronic Publication: 2020 Jan 01 (Print Publication: 2020).